Maplight Therapeutics (NASDAQ:MPLT) CFO Sells $82,149.36 in Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) CFO Jonathan Gillis sold 10,167 shares of the business’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $8.08, for a total transaction of $82,149.36. Following the transaction, the chief financial officer owned 142,315 shares in the company, valued at approximately $1,149,905.20. The trade was a 6.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Maplight Therapeutics Stock Performance

Shares of MPLT traded down $0.32 during trading hours on Friday, reaching $7.70. 359,069 shares of the company traded hands, compared to its average volume of 472,697. The stock’s fifty day moving average is $11.33 and its 200 day moving average is $22.47. The stock has a market cap of $427.94 million and a P/E ratio of -0.18. Maplight Therapeutics, Inc. has a 1-year low of $7.46 and a 1-year high of $40.43.

Maplight Therapeutics (NASDAQ:MPLT) last released its earnings results on Thursday, August 13th. The company reported ($1.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.40) by $0.08. On average, equities research analysts predict that Maplight Therapeutics, Inc. will post -5.01 EPS for the current year.

Institutional Investors Weigh In On Maplight Therapeutics

Several large investors have recently modified their holdings of MPLT. Nan Fung Group Holdings Ltd acquired a new position in shares of Maplight Therapeutics in the 2nd quarter worth approximately $34,809,708. BlackRock Inc. bought a new position in shares of Maplight Therapeutics during the 2nd quarter worth approximately $36,741,000. Blue Owl Capital Holdings LP acquired a new stake in Maplight Therapeutics in the 2nd quarter valued at $26,161,000. ADAR1 Capital Management LLC acquired a new stake in Maplight Therapeutics in the 1st quarter valued at $7,622,000. Finally, 5AM Venture Management LLC bought a new stake in Maplight Therapeutics in the second quarter valued at $34,048,394.

Analyst Ratings Changes

A number of brokerages recently commented on MPLT. BMO Capital Markets began coverage on Maplight Therapeutics in a research note on Monday, July 20th. They issued an “outperform” rating and a $46.00 target price for the company. UBS Group lowered shares of Maplight Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the company from $52.00 to $13.00 in a report on Monday, August 10th. Craig Hallum reissued a “buy” rating and issued a $25.00 price target on shares of Maplight Therapeutics in a report on Tuesday, July 28th. Benchmark restated a “buy” rating on shares of Maplight Therapeutics in a research note on Monday, June 22nd. Finally, Needham & Company LLC reduced their price objective on shares of Maplight Therapeutics from $45.00 to $43.00 and set a “buy” rating for the company in a report on Monday, August 31st. Four research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $29.50.

About Maplight Therapeutics

MapLight Therapeutics is a clinical-stage biopharmaceutical company developing medicines for neuropsychiatric and neurological disorders. The company focuses on conditions for which existing treatments may provide limited benefits or cause significant side effects.

MapLight uses a neuroscience-focused drug discovery and development approach to identify therapies intended to address the underlying biology of central nervous system disorders. Its pipeline includes investigational small-molecule treatments being studied for conditions such as schizophrenia and other serious mental health disorders.

The company conducts research and clinical development in the United States.